Amiodarone is a cardiac drug that is indicated for the management of life-threatening recurrent ventricular fibrillation (VF) or hemodynamically-unstable ventricular tachycardia (VT) refractory to other antiarrhythmic agents, or in patients intolerant of other agents used for these conditions.
Adverse reactions or quality problems experienced with the use of this Product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.
FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another Direct Acting Antiviral drug
FDA Drug Safety Communication: Connection problems involving certain needleless pre-filled glass syringes containing adenosine and amiodarone[ARCHIVED]
Letter to Stakeholders: Communication on certain needleless pre-filled glass syringes[ARCHIVED]
- Information for Healthcare Professionals: Simvastatin (marketed as Zocor), Ezetimibe/Simvastatin (marketed as Vytorin), Niacin extended-release/Simvastatin (marketed as Simcor), used with Amiodarone (Cordarone, Pacerone) [ARCHIVED]
Information on Simvastatin/Amiodarone Information for Healthcare Professionals: Amiodarone (marketed as Cordarone)[ARCHIVED]